Home > Insider Trading > Filing (0001209191-10-033120)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
858803	Avanir Pharmaceuticals Inc.	AVNR	Pharmaceutical Preparations (2834)	330314804

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1350416	Randall Kaye	101 Enterprise, Suite 300 Aliso Viejo CA 92656	Sr. Vp, Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-06-07	50,000	$2.38	304,930	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,250	Indirect	By son
Common Stock	6,250	Indirect	By daughter

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2010 and the proceeds from such sales were used in part to pay required tax withholdings due upon vesting of restricted stock units previously granted to the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.330 to $2.470, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.